Research output: Contribution to journal › Article › peer-review
The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence. / Desheva, Yulia; Kudar, Polina; Sergeeva, Maria; Wong, Pei-fong; Shvedova, Tamara; Bazhenova, Ekaterina; Krylova, Evelyna; Kurpiaeva, Maria; Romanovskaya-romanko, Ekaterina; Krivitskaya, Vera; Kudria, Kira; Isakova-sivak, Irina; Stukova, Marina.
In: International Journal of Molecular Sciences, Vol. 26, No. 15, 7476, 02.08.2025.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence
AU - Desheva, Yulia
AU - Kudar, Polina
AU - Sergeeva, Maria
AU - Wong, Pei-fong
AU - Shvedova, Tamara
AU - Bazhenova, Ekaterina
AU - Krylova, Evelyna
AU - Kurpiaeva, Maria
AU - Romanovskaya-romanko, Ekaterina
AU - Krivitskaya, Vera
AU - Kudria, Kira
AU - Isakova-sivak, Irina
AU - Stukova, Marina
PY - 2025/8/2
Y1 - 2025/8/2
N2 - Influenza B viruses, divided into B/Victoria and B/Yamagata lineages, have not had B/Yamagata isolates after 2020. A study evaluated immunity to influenza B surface antigens hemagglutinin (HA) and neuraminidase (NA) in 138 patient sera from 2023 and 23 pairs of sera from 2018 to 2019 vaccine recipients. The phylogenetic tree of the influenza B virus, based on HA and NA genes, shows that the Yamagata lineage evolves gradually, while the Victoria lineage exhibits rapid mutations with short branches. In 2023, mean levels of antibodies to HA and NA of B/Yamagata virus were higher than to B/Victoria, despite no cases of B/Yamagata lineage isolation after 2020. The titers of antibodies to NA of B/Yamagata statistically significantly differed among individuals born before and after 1988. Among patients examined in 2018-2019, neuraminidase-inhibiting (NI) antibody titers before vaccination were higher to B/Yamagata than to B/Victoria, and NI antibodies to B/Victoria and B/Yamagata positively correlated with neutralizing antibodies to B/Victoria virus before and after vaccination. Immunity to B/Yamagata virus was stronger in 2023, despite no isolation since 2020, probably due to the presence of cross-reactive antibodies from B/Victoria infections or vaccinations. Antibodies to NA of B/Victoria and B/Yamagata in 2023 correlated significantly in patients born before 1988, potentially supporting the concept of 'antigenic sin' phenomenon for influenza B viruses. The fact that NI antibody titers to B/Victoria and B/Yamagata correlated with neutralizing antibody titers to B/Victoria may suggest broad cross-protection. Studying influenza B virus NA antigenic properties helps understand the evolution and antigenic competition of HA and NA.
AB - Influenza B viruses, divided into B/Victoria and B/Yamagata lineages, have not had B/Yamagata isolates after 2020. A study evaluated immunity to influenza B surface antigens hemagglutinin (HA) and neuraminidase (NA) in 138 patient sera from 2023 and 23 pairs of sera from 2018 to 2019 vaccine recipients. The phylogenetic tree of the influenza B virus, based on HA and NA genes, shows that the Yamagata lineage evolves gradually, while the Victoria lineage exhibits rapid mutations with short branches. In 2023, mean levels of antibodies to HA and NA of B/Yamagata virus were higher than to B/Victoria, despite no cases of B/Yamagata lineage isolation after 2020. The titers of antibodies to NA of B/Yamagata statistically significantly differed among individuals born before and after 1988. Among patients examined in 2018-2019, neuraminidase-inhibiting (NI) antibody titers before vaccination were higher to B/Yamagata than to B/Victoria, and NI antibodies to B/Victoria and B/Yamagata positively correlated with neutralizing antibodies to B/Victoria virus before and after vaccination. Immunity to B/Yamagata virus was stronger in 2023, despite no isolation since 2020, probably due to the presence of cross-reactive antibodies from B/Victoria infections or vaccinations. Antibodies to NA of B/Victoria and B/Yamagata in 2023 correlated significantly in patients born before 1988, potentially supporting the concept of 'antigenic sin' phenomenon for influenza B viruses. The fact that NI antibody titers to B/Victoria and B/Yamagata correlated with neutralizing antibody titers to B/Victoria may suggest broad cross-protection. Studying influenza B virus NA antigenic properties helps understand the evolution and antigenic competition of HA and NA.
KW - Adolescent
KW - Adult
KW - Aged
KW - Antibodies, Neutralizing/immunology
KW - Antibodies, Viral/immunology
KW - Cross Reactions/immunology
KW - Female
KW - Hemagglutinin Glycoproteins, Influenza Virus/immunology
KW - Humans
KW - Influenza B virus/immunology
KW - Influenza Vaccines/immunology
KW - Influenza, Human/immunology
KW - Male
KW - Middle Aged
KW - Neuraminidase/immunology
KW - Phylogeny
KW - Viral Proteins/immunology
KW - Young Adult
KW - hemagglutinin (HA)
KW - influenza vaccines
KW - multigene phylogenetic analysis
KW - neuraminidase (NA)
KW - influenza B virus
KW - influenza B virus protein immunology
UR - https://www.mendeley.com/catalogue/ef87c614-05c7-3572-a1e7-a95b41c6be33/
U2 - 10.3390/ijms26157476
DO - 10.3390/ijms26157476
M3 - Article
C2 - 40806604
VL - 26
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1422-0067
IS - 15
M1 - 7476
ER -
ID: 143520840